Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia
Status:
Not yet recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
To study if polyethylene glycol loxenatide plus levonorgestrel-releasing intrauterine system
(LNG-IUS) will improve response rates in patients with endometrial atypical hyperplasia.